Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

450
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
450
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

311
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
311
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

351
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
351
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

308
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
308

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Routine Replacement of Fasting Deficits in Pediatric Ambulatory Anesthesia: A Propensity-Matched Retrospective Cohort Study.

Paediatric anaesthesia·2026
Same author

Thromboembolic Nstemi from a 9.4 × 7.3 mm Mid-Left Circumflex Artery Aneurysm with a Zero Calcium Score and Non-Obstructive Coronary Arteries.

European journal of case reports in internal medicine·2026
Same author

Comparative neurologic toxicity profiles of chemotherapy versus immune checkpoint inhibitors in melanoma: a propensity score-matched analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Improvement in Antimicrobial Stewardship for Orthopaedics Procedures: A NSQIP Quality-Improvement Project.

The Journal of the American Academy of Orthopaedic Surgeons·2026
Same author

Artificial Intelligence-powered tiered early warning framework addressing high false alarm rates for in-hospital mortality prediction.

NPJ digital medicine·2026
Same author

Pulmonary Veno-Occlusive Disease: A Comprehensive Review of Diagnostic Challenges, Therapeutic Limitations, and Evolving Management.

Advances in respiratory medicine·2025

Related Experiment Video

Updated: Jul 23, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.0K

Evidence-Based Approach of Biologic Therapy in Bronchial Asthma.

Adnan Liaqat1, Mathew Mason2, Brian Foster3

  • 1Pulmonary and Critical Care Medicine, McLaren Health/Michigan State University, Flint, MI 48532, USA.

Journal of Clinical Medicine
|July 14, 2023
PubMed
Summary

Biologic agents significantly improve quality of life for severe asthma patients by targeting specific inflammation. Newer therapies like tezepelumab show broad efficacy, reducing exacerbations and steroid needs.

Keywords:
asthmabenralizumabdupilumabmepolizumabomalizumabreslizumabtezepelumab

More Related Videos

A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion
05:56

A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion

Published on: May 12, 2023

3.6K
A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
09:58

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice

Published on: April 13, 2010

22.5K

Related Experiment Videos

Last Updated: Jul 23, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.0K
A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion
05:56

A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion

Published on: May 12, 2023

3.6K
A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
09:58

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice

Published on: April 13, 2010

22.5K

Area of Science:

  • Pulmonology and Immunology
  • Pharmacology

Background:

  • Biologic agents represent a significant advancement in managing bronchial asthma.
  • These therapies target specific inflammatory pathways, particularly Type 2 inflammation, crucial in severe eosinophilic asthma.
  • Current treatments aim to improve patient quality of life and reduce healthcare utilization.

Purpose of the Study:

  • To review the pathophysiologic mechanisms of biologic therapies for asthma.
  • To provide an evidence-based discussion on the indications, benefits, and adverse effects of these treatments.
  • To highlight the role of newer agents like tezepelumab.

Main Methods:

  • Review of randomized controlled trials (RCTs) evaluating biologic agents in asthma.
  • Analysis of studies assessing efficacy in reducing exacerbation rates and glucocorticoid dosages.
  • Examination of data on tezepelumab's effectiveness across different asthma phenotypes and biomarker levels.

Main Results:

  • Biologic therapies have demonstrated effectiveness in reducing asthma exacerbations.
  • These agents can lead to decreased requirements for glucocorticoid medications.
  • Tezepelumab shows efficacy irrespective of specific asthma phenotypes or serum biomarker levels.

Conclusions:

  • Biologic therapies offer substantial benefits for patients with severe asthma.
  • Understanding the mechanisms and evidence base is crucial for optimal clinical application.
  • Tezepelumab represents a promising therapeutic option with broad applicability in asthma management.